| 1492 |
National Cancer Institute |
Html |
en |
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version |
For acute lymphoblastic leukemia (ALL), the 5-year survival rate rose from 60% to about 90% for children younger than 15 years and from 28% to about 75% for adolescents aged 15–19 years between 1975 and 2010. Get information about risk factors, signs, diagnosis, genomics, survival, risk-based treatment assignment, and induction and postinduction therapy for children and adolescents with newly diagnosed and recurrent ALL. |
| prognostic factors | 0.457078 |
| B-Cell Acute Lymphoblastic | 0.477707 |
| Cancer Statistics Review | 0.442138 |
| B-acute lymphoblastic leukemia | 0.487736 |
| Leukemia Group | 0.457445 |
| children | 0.485859 |
| childhood lymphoblastic leukaemia | 0.461366 |
| acute lymphoblastic leukaemia | 0.619966 |
| acute lymphoblastic leukemias | 0.490719 |
| leukemia cells. | 0.443609 |
| prognostic significance | 0.464566 |
| Nat Genet | 0.45804 |
| leukemia susceptibility gene | 0.452718 |
| Hyperdiploid leukemia cells | 0.447496 |
| et al. | 0.591777 |
| SEER Cancer Statistics | 0.449829 |
| lymphoblastic leukemia consortium | 0.485454 |
| childhood acute leukemias | 0.444646 |
| frank leukemia | 0.449613 |
| Br J Haematol | 0.473302 |
| early T-cell precursor | 0.46793 |
| PUBMED Abstract | 0.469887 |
| concordant leukemia | 0.449352 |
| residual leukemia | 0.447727 |
| Pediatr Blood Cancer | 0.49042 |
|
| acute lymphocytic leukemia | 0.489397 |
| Leukemia Study Group | 0.454229 |
| National Cancer Institute | 0.475056 |
| acute lymphoblastic leukaemias | 0.494907 |
| childhood leukemia | 0.453157 |
| outcome | 0.442439 |
| myeloid leukemia stem | 0.447271 |
| lymphoblastic leukemia risk | 0.49811 |
| lymphoblastic leukaemia aetiology | 0.462653 |
| childhood | 0.471724 |
| Abstract | 0.585405 |
| Acute leukaemia | 0.444978 |
| cancer group | 0.443895 |
| Pediatr Hematol Oncol | 0.438989 |
| Clin Oncol | 0.520227 |
| Pediatric Oncology Group | 0.440216 |
| infant leukemia | 0.443122 |
| acute promyelocytic leukemia | 0.469574 |
| acute lymphoblastic leukemia | 0.925289 |
| acute leukemia | 0.478163 |
| Lymphoblastic Leukemia Treated | 0.486039 |
| Children Leukemia Group | 0.457299 |
| leukemia cells | 0.45331 |
| oncology group | 0.497434 |
|
CLICK HERE |
| 1536 |
National Cancer Institute |
Html |
en |
Laetrile/Amygdalin (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of laetrile/amygdalin as a treatment for people with cancer. |
| cancer treatment | 0.52441 |
| cancer cell inhibitors. | 0.542345 |
| intravenous amygdalin treatment | 0.677872 |
| amygdalin occurs | 0.621015 |
| potential anticancer activity | 0.529695 |
| cyanide poisoning | 0.73495 |
| blood cyanide levels | 0.657623 |
| intestinal bacteria | 0.607185 |
| primordial germ cells | 0.521102 |
| purported anticancer activity | 0.532782 |
| oral amygdalin | 0.650441 |
| cancer patients | 0.590892 |
| complete responses | 0.526167 |
| high-dose vitamin supplements | 0.5155 |
| metabolic therapy | 0.516142 |
| U.S.-patented Laetrile | 0.757295 |
| laetrile therapy | 0.736124 |
| amygdalin interacts | 0.616968 |
| laetrile’s breakdown | 0.71917 |
| laetrile practitioners. | 0.705315 |
| anticancer activity | 0.587095 |
| nontoxic intravenous form | 0.531127 |
| specific anticancer properties | 0.534462 |
| intravenous Laetrile | 0.740226 |
| United States | 0.629681 |
|
| positive results | 0.563482 |
| case series | 0.523576 |
| cancer cells | 0.637689 |
| oral maintenance therapy | 0.601513 |
| colon cancer cells | 0.550218 |
| promising cancer therapies | 0.544057 |
| term laetrile | 0.84507 |
| human breast cancer | 0.525831 |
| laetrile treatment. | 0.765844 |
| higher-dose amygdalin therapy | 0.65865 |
| National Cancer Institute | 0.610445 |
| cyanide anion | 0.594345 |
| partial responses | 0.519394 |
| Laetrile supporters | 0.777243 |
| term vitamin B-17 | 0.520783 |
| amygdalin | 0.757648 |
| enzyme beta-glucosidase | 0.562945 |
| anticancer agent | 0.587895 |
| case reports | 0.550533 |
| hydrogen cyanide | 0.876372 |
| cyanide group | 0.578561 |
| laetrile | 0.994496 |
| chemical amygdalin | 0.642935 |
| cancer | 0.720035 |
|
CLICK HERE |
| 1565 |
National Cancer Institute |
Html |
null |
Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of lip and oral cavity cancer. |
|
|
CLICK HERE |
| 1584 |
National Cancer Institute |
Html |
en |
Anal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of anal cancer. |
| cancer treatment | 0.433322 |
| diagnose anal cancer | 0.423593 |
| Anal Cancer Treatment | 0.419952 |
| metastatic anal cancer | 0.412176 |
| Frequent anal redness | 0.384126 |
| body | 0.434753 |
| PDQ cancer information | 0.446236 |
| clinical trial search | 0.504831 |
| anal cancer spreads | 0.410812 |
| clinical trials | 0.887836 |
| cancer information summary | 0.419039 |
| clinical trial | 0.647154 |
| anus | 0.449257 |
| patients | 0.429875 |
| treatment clinical trial | 0.380816 |
| NCI PDQ cancer | 0.384659 |
| malignant tumor cells | 0.380765 |
| radiation therapy | 0.718553 |
| Treatment Editorial Board | 0.382929 |
| human immunodeficiency virus | 0.375987 |
| rectum | 0.3805 |
| General information | 0.426863 |
| general cancer information | 0.376766 |
| treatment | 0.612453 |
| abdominoperineal resection | 0.403255 |
|
| receptive anal intercourse | 0.384527 |
| new cancer treatments | 0.377037 |
| NCI-supported cancer | 0.425485 |
| cancer cells | 0.46124 |
| Cancer Information Service | 0.376813 |
| sphincter muscles | 0.384557 |
| treatment clinical trials | 0.40741 |
| National Cancer Institute | 0.461854 |
| Recurrent anal cancer | 0.435676 |
| new treatment | 0.505194 |
| external-beam radiation therapy | 0.454262 |
| IIIA anal cancer | 0.402258 |
| IIIB anal cancer | 0.401297 |
| anal cancer | 0.792189 |
| new treatment options | 0.426789 |
| anal opening | 0.376839 |
| cancer clinical trials | 0.506964 |
| stage | 0.400723 |
| Local resection | 0.453758 |
| tumor | 0.401265 |
| comprehensive cancer information | 0.375327 |
| internal radiation therapy | 0.496063 |
| cancer | 0.970468 |
| information | 0.453326 |
|
CLICK HERE |
| 1640 |
National Cancer Institute |
Html |
en |
Newcastle Disease Virus (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of Newcastle disease virus (NDV) as a treatment for people with cancer. |
| cancer treatment | 0.693563 |
| cancer vaccines | 0.521674 |
| NDV exposure | 0.572848 |
| PDQ cancer information | 0.607302 |
| NDV oncolysates | 0.62702 |
| NDV oncolysate vaccine | 0.595653 |
| Cancer Complementary | 0.497162 |
| clinical trials | 0.82691 |
| cancer information summary | 0.562857 |
| alternative cancer therapies | 0.50194 |
| cancer cells | 0.76191 |
| clinical trial | 0.614089 |
| cancer cell membranes | 0.494977 |
| CAM cancer research | 0.494494 |
| patients | 0.577416 |
| cancer patients | 0.492391 |
| NCI PDQ cancer | 0.521504 |
| normal human cells | 0.563305 |
| Therapies Editorial Board | 0.503966 |
| mild flu-like symptoms | 0.510261 |
| cancer information | 0.619682 |
| United States | 0.526285 |
| Complementary Therapies Editorial | 0.520012 |
| Drug Administration | 0.499837 |
|
| Cancer Information Specialist | 0.497536 |
| newcastle disease virus | 0.991038 |
| Cancer Information Service | 0.562079 |
| whole-cell vaccines | 0.564502 |
| preclinical studies | 0.493829 |
| treatment clinical trials | 0.498071 |
| National Cancer Institute | 0.661651 |
| studies | 0.639134 |
| alternative medicine | 0.578409 |
| host cells | 0.500132 |
| long-term cancer immunity | 0.490137 |
| NDV | 0.932374 |
| new treatment | 0.535357 |
| way NDV | 0.585949 |
| NDV-infected cancer cells | 0.522696 |
| NDV strain MTH-68 | 0.598465 |
| human cancer cells | 0.635784 |
| cancer clinical trials | 0.51669 |
| alternative therapies | 0.521775 |
| used animal cells | 0.494675 |
| cancer information summaries | 0.502326 |
| comprehensive cancer information | 0.502048 |
| possible cancer treatment | 0.568987 |
| cancer | 0.97648 |
|
CLICK HERE |
| 1724 |
National Cancer Institute |
Html |
en |
HPV and Cancer |
A fact sheet about the link between human papillomaviruses (HPV) infection and cancer. |
| common HPV test | 0.550757 |
| HPV prophylactic vaccines | 0.525058 |
| HPV transmission | 0.523742 |
| HPV types | 0.851794 |
| new HPV infections | 0.590343 |
| HPV cause cancer | 0.569767 |
| new genital HPV | 0.595653 |
| Disease Control | 0.420832 |
| HPV vaccination coverage | 0.520008 |
| High-risk HPVs cause | 0.396129 |
| cervical cancer screening | 0.405825 |
| Sexually transmitted HPV | 0.603413 |
| cervical cancer | 0.502612 |
| high-risk HPV infections | 0.626562 |
| cervical human papillomavirus | 0.402943 |
| genital HPV infection | 0.55616 |
| human papillomavirus infection | 0.459361 |
| high-risk hpv types | 0.826201 |
| high-risk hpv | 0.840346 |
| human papillomavirus | 0.53728 |
| cancers | 0.432231 |
| HPV-positive oropharyngeal cancer | 0.40701 |
| HPV infections | 0.970786 |
| genital HPV infections | 0.683801 |
| contact. HPV infections | 0.593955 |
|
| HPV vaccination | 0.54978 |
| United States | 0.529252 |
| initial HPV infection | 0.546638 |
| oropharyngeal cancers | 0.43202 |
| dozen high-risk HPV | 0.602317 |
| HPV | 0.989222 |
| genital warts | 0.416311 |
| invasive cervical cancer | 0.399038 |
| sexually transmitted infections | 0.459394 |
| -negative oropharyngeal cancer | 0.400863 |
| precancerous cervical changes | 0.395202 |
| primary cervical cancer | 0.407999 |
| high-risk HPV type | 0.63373 |
| genital human papillomavirus | 0.479948 |
| high-risk hpvs | 0.421752 |
| HPV tests | 0.525251 |
| cervical intraepithelial neoplasia | 0.425761 |
| Sexually Transmitted Diseases | 0.450013 |
| abnormal cell changes | 0.409947 |
| persistent HPV infections | 0.582609 |
| respiratory tract tumors | 0.390546 |
| et al | 0.566033 |
| oropharyngeal cancer | 0.468234 |
| cell changes | 0.431517 |
|
CLICK HERE |
| 2022 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de cuello uterino (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre los exámenes que se utilizan para detectar el cáncer de cuello uterino. |
| siguientes grupos | 0.30039 |
| PDQ Exámenes | 0.300773 |
| Physician Data Query | 0.301635 |
| libre uso | 0.300195 |
| cuello uterino | 0.99515 |
| prevención revisa | 0.300275 |
| largo plazo | 0.300411 |
|
| principal factor | 0.302387 |
| información ayuda | 0.300455 |
| National Cancer Institute | 0.300349 |
| siguientes riesgos | 0.300249 |
| siguientes sumarios | 0.301285 |
| Instituto Nacional | 0.300751 |
|
CLICK HERE |
| 2965 |
National Cancer Institute |
Html |
en |
Menthol Cigarettes |
Learn more about Menthol Cigarettes, including how they are used by cigarette companies, their effects, and some common myths. |
| hookah water pipe | 0.494728 |
| large premium cigars | 0.459683 |
| oral tobacco | 0.537822 |
| greater risks | 0.403027 |
| cancer-causing substances | 0.387897 |
| chemical additives | 0.392918 |
| burning cigarette | 0.414008 |
| throat cancer | 0.383899 |
| lung cancer | 0.382731 |
| tobacco | 0.978071 |
| supportive friends | 0.453267 |
| cancer-causing chemicals | 0.389232 |
| hookah smoke | 0.446625 |
| Cigar smoke | 0.40643 |
| greater health issues | 0.438887 |
| carbon monoxide | 0.384792 |
| cigar tobacco | 0.526627 |
| paper wrapping | 0.393371 |
| leaf tobacco | 0.522574 |
| tobacco products | 0.765605 |
| harm brain development | 0.443591 |
| high risk | 0.381422 |
| little filtered cigars | 0.462027 |
| older siblings | 0.385847 |
| Hookah tobacco | 0.577414 |
|
| healthy way | 0.432788 |
| Nicotine exposure | 0.405523 |
| toxic chemicals | 0.388306 |
| harmless water vapor | 0.448644 |
| potentially harmful chemicals | 0.482948 |
| high levels | 0.460808 |
| health consequences | 0.391113 |
| cigarette smoke | 0.424559 |
| cigarette smoking | 0.578732 |
| heart disease | 0.388527 |
| DipfreeTXT program | 0.386418 |
| vape pens | 0.380351 |
| hookah smoking | 0.490187 |
| multiple tobacco products | 0.584428 |
| spitting tobacco | 0.542435 |
| mouth cancer | 0.379991 |
| size—from smaller cigars | 0.460695 |
| cigarette tobacco | 0.544703 |
| Cigar users | 0.389386 |
| quitSTART app | 0.388192 |
| e-cigarettes | 0.388072 |
| smokeless tobacco | 0.780551 |
| risks | 0.529273 |
| health risks | 0.470569 |
|
CLICK HERE |
| 4134 |
National Cancer Institute |
Html |
es |
Papás que tienen a un niño con cáncer |
Información práctica para los padres, cuando un hijo tiene cáncer. Sugerencias para ayudar a los niños y a los padres a salir adelante y mantenerse fuertes; junto con respuestas a preguntas que padres e hijos hacen con frecuencia. |
| niño hable | 0.533769 |
| vidas—sus amistades | 0.451463 |
| tratamiento causa | 0.442235 |
| creatividad usted | 0.438948 |
| relaciones estables respete | 0.423362 |
| busque formas | 0.809977 |
|
| children with cancer | 0.982284 |
| niño lucha | 0.578927 |
| niño trabaje | 0.532596 |
| When Your Brother | 0.434468 |
| largas estancias | 0.426928 |
| tus doctores | 0.503446 |
|
CLICK HERE |
| 17293 |
National Cancer Institute |
Html |
es |
Falta de apetito |
Información y consejos para controlar la falta de apetito, un efecto secundario del tratamiento del cáncer. |
| siguientes medidas | 0.7116 |
| cáncer pdf | 0.657674 |
| causa dificultad | 0.715293 |
|
| complementos alimenticios | 0.63897 |
| suficiente lÃquido | 0.951874 |
| alto contenido | 0.653742 |
|
CLICK HERE |